The National TB Controllers Association (NTCA) has learned that the U.S. Food & Drug Administration (FDA) has removed APLISOL® from its current shortage listing. APLISOL® is now listed on the CBER-Regulated Products: Resolved Shortages webpage. 

In response to a call from NTCA, the manufacturer of APLISOL®, Par Pharmaceutical Companies Inc., stated that all geographic markets/wholesalers throughout the US should have adequate inventory now. In another call, Sanofi confirmed that Tubersol® is still in allocation and that the company still anticipated an 8/31 assessment date to know if allocation would continue. 

Programs are encouraged to let NTCA know if you are having continued challenges procuring either PPD solution using the NTCA's TB Drugs & Diagnostics Shortages Reporting Form.